13F Holdings
中文EN

MIRM Mirum Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1759425 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY42.2%
TTM net income YoY-2,082.1%
TTM EPS YoY-1,622.6%
Revenue 3-yr CAGR66.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-133.6%
Net margin-134.8%
FCF margin-40.8%
EBITDA margin-129.6%

Returns

ROE-760.0%
ROA-99.8%
ROIC (approx.)—
Asset turnover0.74x

Leverage & solvency

Liabilities / assets105.3%
Debt / equity—
Current ratio2.07x
Interest coverage-78.36x

Cash quality & payout

Operating cash flow / net income0.30x
Accruals ratio-69.8%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$521.31M$336.89M$186.37M$77.06M$19.14M
R&D expense$186.18M$140.63M$102.61M$106.84M$131.43M
SG&A expense$257.03M$202.22M$145.88M$89.07M$59.22M
Operating income-$22.14M-$87.61M-$109.15M-$131.22M-$173.41M
Interest expense$14.39M$14.31M$15.11M$15.98M—
Pretax income-$21.43M-$86.91M-$162.42M-$142.07M-$83.95M
Income tax$1.94M$1.03M$991,000-$6.41M$37,000
Net income-$23.36M-$87.94M-$163.41M-$135.66M-$83.99M
EBITDA$2.11M-$63.98M-$98.33M-$127.98M-$172.82M
EPS (basic)-0.47-1.85-4.00-4.01-2.77
EPS (diluted)-0.47-1.85-4.00-4.02-2.77
Weighted avg. shares (diluted)50.20M47.52M40.89M33.98M30.32M
Balance sheet
Cash & equivalents$296.68M$222.50M$286.33M$28.00M$31.34M
Short-term investments$86.64M$57.81M$0$123.72M$125.20M
Receivables$123.33M$78.29M$67.97M$23.99M$3.27M
Inventory$24.89M$22.40M$22.31M$5.57M$1.51M
Current assets$549.68M$392.79M$387.54M$190.22M$166.59M
PP&E, net$1.86M$1.14M$706,000$914,000$981,000
Intangibles$260.92M$249.82M$252.93M$58.95M$18.74M
Total assets$842.81M$670.75M$646.62M$352.91M$294.65M
Current liabilities$205.80M$126.55M$87.06M$64.73M$42.60M
Total liabilities$528.12M$445.11M$397.95M$210.87M$174.44M
Shareholders' equity$314.69M$225.64M$248.67M$142.04M$120.21M
Shares outstanding51.90M48.34M46.72M36.96M30.58M
Cash flow statement
Operating cash flow$55.83M$10.32M-$70.94M-$120.14M-$132.76M
Capital expenditure$954,000$993,000$109,000$278,000$24,000
Free cash flow$54.87M$9.33M-$71.05M-$120.41M-$132.78M
Investing cash flow-$23.95M-$90.12M-$107.20M$7.70M$48.55M
Financing cash flow$40.14M$17.70M$336.60M$109.09M$73.47M
Depreciation & amortization$24.24M$23.63M$10.83M$3.24M$595,000
Stock-based compensation$71.42M$48.44M$35.02M$27.01M$23.09M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.